Innoviva, Inc.

Healthcare · Biotechnology

Overall research band Mixed

Quality Mixed

Valuation Exceptional

Balance sheet Above average

Market confirmation Very weak

One-minute company read

What this report can tell you now

What the company does

Innoviva, Inc. is a pharmaceutical company based in Burlingame, California, focused on the global development and commercialization of medical treatments. Its main products are once-daily combination therapies for respiratory diseases, including RELVAR/BREO ELLIPTA (vilanterol and fluticasone furoate), ANORO ELLIPTA (umeclidinium bromide and vilanterol), and TRELEGY ELLIPTA (a combination of an inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting beta2 agonist). Innoviva's customers are healthcare providers and patients with chronic obstructive pulmonary disease and asthma. The company generates revenue through strategic collaborations, notably with Glaxo Group Limited, for the development and commercialization of LABA-based products, and maintains a key alliance with Sarissa Capital Management LP.

The current research profile is Mixed Setup, with high valuation support. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

No single strength should be treated as decisive without reviewing the underlying evidence and data status.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

Read the latest filing or company update.
Check the financial period behind each metric.
Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC15.7%Model input; read with the evidence status and period context.

Operating margin38.5%Model input; read with the evidence status and period context.

Revenue CAGR · 4 years2.1%Model input; read with the evidence status and period context.

FCF margin43.9%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.

Evidence detailSee exact inputs, source context, and model-aware metrics.

HistoryReview score and research changes over time.

MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.